Navigation Links
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Date:6/26/2008

said Charles A. Czeisler, PhD, MD, FRCP, Chairman of Vanda's Scientific Advisory Board.

This study also demonstrated that tasimelteon was well-tolerated and exhibited a safety profile generally similar to placebo.

About Tasimelteon

Tasimelteon, (VEC-162), is Vanda's novel melatonin agonist in development for the treatment of insomnia and circadian rhythm sleep disorders (CRSD). Researchers believe that the interplay between the MT-1 and MT-2 pathways and environmental signals such as external light-dark cues results in the drive for wakefulness during daytime hours and sleepiness during night-time hours.(1) In patients with insomnia or CRSD, the regulation of the sleep/wake cycle is disrupted.(2) By binding to both the MT-1 and MT-2 receptors in a balanced fashion, tasimelteon helps modulate the patient's circadian rhythm, re-setting the sleep/wake cycle and providing simultaneous, immediate sleep- promoting benefits.(1)

About Insomnia and Circadian Rhythm Sleep Disorders

Insomnia, the most common sleep disorder, affects approximately 50-70 million American adults.(3,4) It is characterized by difficulty falling asleep, waking frequently during the night, waking too early and not being able to return to sleep, or waking up and not feeling refreshed.(5)

CRSD, another type of sleep disorder defined as the inability to sleep at usual or customary times, affects millions of Americans in a number of forms, including Shift Work Disorder, which affects 10% of Americans who are shift workers; Delayed Sleep Phase Disorder, which affects 5-10% of chronic insomnia patients; and Jet Lag Disorder, which typically affects air travelers crossing five or more time zones.(6-8)

Conference Call

The company has scheduled a conference call for today, Thursday, June 26, 2008 at 10:00 AM ET. During the call, Mihael H. Polymeropoulos, M.D., Vanda's President and CEO, will discuss the trial results. Investors can call 1-866-831-6162 (d
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or ... Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) ... Diseases (NIAID), a division of the National Institutes ... human antibody therapeutics to combat Staphylococcus aureus ... including methicillin-resistant S. aureus (MRSA), was ...
(Date:5/17/2013)... CHAMPAIGN, Ill. , May 17, 2013  Sony ... new Sony SP6800 Spectral Analyzer (SP6800).  Sony will be ... 2013, which will be held at the ... San Diego, California , from May 20 - ... Sony,s second analytical system, incorporating commercial audio-visual technologies into ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- The escalation of new ... placing renewed emphasis on alternate delivery technologies. Alternate ... number of factors are converging to create both ... their delivery device partners . These include new ... growing trend toward self-administration for chronic diseases, shifting ...
Breaking Medicine Technology:Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3
... , July 16 Warner Chilcott ... received a communication from the U.S. Food & Drug Administration ... delayed-release tablets extending the Prescription Drug User Fee Act (PDUFA) ... additional information solicited by the FDA and previously provided by ...
... , July 15 LyoTechnica, LLC has ... drug development services for injectable pharmaceuticals. The company and ... in lyophilization and liquid dosage form development as well ... of parenteral drugs. The company offers analytical and formulation ...
Cached Medicine Technology:Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product 2Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product 3Formation of Contract Parenteral Drug Development Services Company Announced 2
(Date:5/18/2013)... Orlando, FL (May 18, 2013) A ground-breaking ... colorectal care, according to research presented today at ... optimizing the minimal withdrawal time for colonoscopies and ... , During colonoscopy, doctors use a device called ... test for colorectal cancer allows a doctor to ...
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... pelvic mesh products continue to move forward in a ... Court, Bernstein Liebhard LLP reports. According to a notice ... in the Ethicon pelvic mesh litigation will be held ... 2,755 complaints have been filed in the proceeding on ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- ... drink, but new research shows that college women are more ... basis than are college men. Much of this ... safe on a weekly basis is much lower for women ... 14 for men. But, there,s good reason for that difference. ...
(Date:5/18/2013)... After working diligently for months and putting in ... the integration of the fitment specs for the redesigned 2012 ... stun the automobile market with its extraordinary features and unique ... as the latest entry in the size it up ... the year 2013. , Aptly suiting its name, 2012 ...
(Date:5/18/2013)... 2013 Family Magazine of Washington DC was ... Follow Media Consulting, Inc. in the category of Summer ... and dedication of the areas best in the ultimate guide ... parenting better than Brenda Hyde, a mother of four and ... know about the vast resources available to them in the ...
Breaking Medicine News(10 mins):Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2
... suitable treatment mode for women diagnosed with breast cancer who ... should consider hormonal treatments to reduce their risk of a ... study led by researchers at the University of Michigan Comprehensive ... genetic mutation who had their ovaries removed or took the ...
... as a custom rather than as a matter of choice. ... waywardness //in the females while some clans even consider it ... initiating teenage girls into adulthood. ,As tradition goes ... which are often unsterilized. In addition the area of excision ...
... in regulating cell death, a Queen’s University study has found. ... be used to promote cell death in cancer cells but ... in neuronal cells in the case of Alzheimer’s or Parkinson’s. ... Medicine with the Cancer Biology and Genetics division of Queen’s ...
... new survey nearly 12 million Americans are affected by peripheral ... arteries are blocked that brings blood to the legs due ... is likely to increase in the coming decades and it’s ... drugs to treat it. , ,By examining the physiology ...
... sector educational group Amity Institutions have decided to launch ... plans to set up academic and training infrastructure in ... in an effort to expand the educational facilities in ... President, and board member of Ritnand Balved Education Foundation, ...
... the breast cancer in younger black women nothing significant has ... women the number of black women affected by breast cancer ... the black women is much higher when compared with the ... 50 have a 77 percent of mortality rate. ...
Cached Medicine News:Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 2Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 3Health News:Female Circumcision Rampant in Africa 2Health News:Protein’s role in regulating cell death sets direction for Alzheimer’s, Parkinson’s and cancer resea 2Health News:New Test to Diagnose the Peripheral Arterial Disease (PAD) 2Health News:Breast Cancer Mortality Rate is Higher Among Black Women 2Health News:Breast Cancer Mortality Rate is Higher Among Black Women 3
The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
The Onar®Lp -QP test system is an in vitro test for the quantitative diagnosis of legionella in clinical samples....
Designed for OSA patients who have difficulty with conventional CPAP therapy, the ResMed SULLIVAN Comfort system is a solution for those who need an alternative to CPAP....
... an approach to treatment that ... pressure range to 25 cm ... treat patients with severe OSA. ... integrated humidification and built-in Encore® ...
Medicine Products: